Twitter Beğeni Hilesi

Our CEO, Dr. Edward M. Kaye, shares what brought him to #biotech, the importance of taking risks, and Stoke’s work in #DravetSyndrome with Boston Business Journal. Read the full story: bizj.us/1qlcuz

Decision-making in biotech should always focus on what’s best for patients. Stoke CEO Dr. Edward M. Kaye will discuss how to maintain patient-centric focus in a panel discussion at Longwood Healthcare Leaders Spring MIT. longwoodhealthcareleaders.com/spring2024 #longwoodhealthcareleaders @longwoodfund

10 years ago, Isabel Aznarez 🏳️‍🌈🇺🇦🥥🌴 & Adrian Krainer built Stoke rooted in their passion for science, making a difference in patients’ lives & entrepreneurial spirit. As we reflect, our co-founders share memories from early days. stoketherapeutics.com/about-stoke/fo… #StokedAboutStoke

Cheers to 10 years of Stoke 🎉 In the last decade, we’ve made strides in our research, grown our pipeline, and cultivated a culture that strikes a balance between serious work and fun. #StokedAboutStoke

#DravetAwarenessMonth sheds light on the experiences of patients and families who are impacted by this severe disease. Learn more about one family’s journey navigating Dravet syndrome in BBC. bbc.com/news/articles/… Dravet Syndrome UK

The Stoke team is attending Dravet Syndrome Foundation’s Biennial Conference! Our VP, Head of Neurology Clinical Development, Kimberly Parkerson, will provide an update on our #DravetSyndrome clinical program. Learn more about the event: dravetfoundation.org/events/dsf-con… #curedravet #DravetAwareness

During #PrideMonth, we’re celebrating the LGBTQIA+ community, which includes our co-founder, @Isa_aznarez! Isa is a driving force behind our commitment to #DEI & reminds us to be our authentic selves. Read about Isa & other LGBTQIA+ industry leaders: endpts.com/15-leaders-giv…

What to know on #SyngapAwarenessDay: This rare neurodevelopmental disorder is characterized by moderate to severe intellectual disability in early childhood. There are currently no approved treatments for Syngap1. Learn more about the disease: stoketherapeutics.com/disease-areas/… #SYNGAP1

It's #DravetAwarenessDay. Can you share our film to reach more people in need of our support? #LittleMomentsMatter shares what 3 families love about their children, what they don't love about #DravetSyndrome & how DSUK has supported them. Park Lane Stables MeathEpilepsyCharity

June was full of #DravetAwarenessMonth events! 🦋We welcomed a patient family to share experiences living with #Dravetsyndrome. 🦋We participated in Dravet Syndrome Foundation’s t-shirt fundraiser. 🦋We came together to create art for our office featuring butterflies, which symbolize hope.

This year’s DSF Biennial Conference allowed our team to connect with patient families, advocates, and other life science companies dedicated to helping those impacted by #DravetSyndrome. Thank you Dravet Syndrome Foundation for hosting another impactful event. #curedravet #DravetAwareness

As we advance our science to address the underlying cause of severe diseases, we also believe in celebrating our journey as a team! Explore photos from our 10-year anniversary festivities! 🎊 #StokedAboutStoke

"From his clinical practice through to his current role leading Stoke Therapeutics, Dr. Edward Kaye has spent his career trying to treat rare pediatric genetic diseases." #ICYMI our CEO discussed #biotech leadership, including Stoke’s work in Dravet: bizj.us/1qlcuz

TOMORROW: Stoke CEO Dr. Edward Kaye will discuss leadership strategies for #biotech executives at Boston Business Journal's Biotech in Boston: Leading the Way in Life Sciences. Register today: bizjournals.com/boston/event/1… #BBJLifeSciences

At Stoke, we are on a mission to restore protein expression by harnessing the body's potential with #RNA medicine. This #RNADay, learn more about the promise of this “long-overlooked molecule” in The New York Times: nytimes.com/2024/05/29/opi…

Today, we reported our Q2 2024 #FinancialResults and provided business updates: investor.stoketherapeutics.com/news-releases/…

Our CEO Dr. Edward Kaye sat down with Brad Loncar of BiotechTV to discuss why he’s so excited to be leading Stoke in our mission to change the way severe diseases are treated by upregulating protein expression with #RNA-based medicines. Watch here:

The Stoke team is heading to ILAE’s 15th European #Epilepsy Congress in Rome! We look forward to sharing encore data from our #Dravetsyndrome clinical program. Learn more about our upcoming presentations: investor.stoketherapeutics.com/news-releases/… #EEC2024 #ILAE

Today we announced upcoming investor conference presentations at H.C. Wainwright & Co.’s 26th Annual Global Investment Conference and Cantor Fitzgerald’s 2024 Global Healthcare Conference. Learn more: investor.stoketherapeutics.com/news-releases/… #CantorHCC #Biotech #innovation #investment

Stoke is pleased to announce the appointment of Eric Olson as Chief Business Officer. Mr. Olson brings two decades of successful corporate business development experience with an emphasis on #rarediseases and #RNA therapeutics investor.stoketherapeutics.com/news-releases/…